Selank on Amino Club

Use code BHACK at checkout for 20% off (auto-applied via the link above)

What Is Selank?

Selank is a synthetic heptapeptide consisting of seven amino acids, derived from the natural immunomodulatory peptide tuftsin with the addition of a stabilizing tetrapeptide tail. The molecule was developed as a research compound for investigating anxiolytic and neuroregulatory effects through GABAergic and other neurotransmitter pathways. Research interest has focused on its observed effects on anxiety-like behaviors in animal models, its modulation of immune-nervous system interactions, and its profile as a non-sedating anxiolytic candidate.

Discovery and Background

Selank was developed at the V.V. Zakusov Institute of Pharmacology of the Russian Academy of Sciences during the 1990s, as part of broader Russian research into peptide-based neuroregulators. The compound's design built on earlier work with tuftsin, a naturally occurring four-amino-acid peptide identified in the 1970s that demonstrated immunomodulatory activity. Researchers added a stabilizing C-terminal tetrapeptide sequence (Pro-Gly-Pro) to tuftsin to extend its biological half-life, producing the seven-amino-acid Selank molecule. The compound has been registered as a medication in Russia for the treatment of generalized anxiety disorder, where it is administered as an intranasal solution. Selank remains primarily a research compound in Western contexts, with most published studies originating from Russian research institutions.

Mechanism of Action

Research indicates Selank exerts its effects through multiple mechanisms including modulation of GABAergic neurotransmission, alterations in serotonin metabolism, and effects on enkephalin degradation. Studies have documented Selank-induced changes in expression of genes encoding GABA-A receptor subunits, with particular effects on receptor density in regions associated with anxiety regulation. Research has also reported the peptide's effects on brain-derived neurotrophic factor (BDNF) expression, anti-inflammatory cytokine modulation, and stabilization of enkephalin levels through inhibition of degradation. The compound has been described as producing anxiolytic effects without the sedation or dependence associated with benzodiazepines.

Areas of Research Interest

• Anxiety and stress response studies
• Generalized anxiety disorder research
• Cognitive function and memory studies
• Immunomodulation research
• Neuroinflammation studies
• Depression and mood research
• Stress-induced gastrointestinal models

Notable Studies in the Literature

• Kozlovskaya et al. (2003) published in Bulletin of Experimental Biology and Medicine documenting Selank's anxiolytic effects in rat models comparable to benzodiazepine reference compounds without associated sedation
• Semenova et al. (2007) reported clinical research on Selank in patients with generalized anxiety disorder, with reported reductions in anxiety scores following intranasal administration
• Volkova et al. (2016) investigated Selank's effects on gene expression in rat brain tissue, documenting changes in expression of multiple neurotransmitter and stress-related genes
• Research published in Russian Journal of Bioorganic Chemistry has reviewed Selank's pharmacology including its neurotransmitter modulation profile
• Multiple animal studies have documented Selank's effects on learning and memory parameters in stress models, with reports of cognitive preservation under stress conditions

Reported Findings in the Literature

• Studies have reported anxiolytic effects in animal models without sedation
• Research has documented cognitive preservation under stress conditions in rat models
• Investigations have shown modulation of GABAergic gene expression in brain tissue
• Animal studies have reported anti-inflammatory effects in neuroinflammation models
• Clinical research has documented anxiety reduction in human subjects with anxiety disorders
• Immunomodulation studies have reported balanced effects on cytokine profiles

Safety Profile in Research

Selank has been studied in both animal research and Russian clinical contexts, providing a moderate safety database compared to many research peptides. The compound's clinical use in Russia for anxiety disorders has generated a body of post-marketing observation data, with reports generally describing favorable tolerability. Reported adverse events in available research have included mild nasal irritation with intranasal administration (the registered route in Russia), occasional headache, and rare reports of transient dizziness.

The compound has not demonstrated sedative effects at therapeutic doses, distinguishing it from benzodiazepine-class anxiolytics. Selank has not been reported to produce dependence, withdrawal symptoms, or cognitive impairment in available research, which has been considered a notable advantage in its profile relative to traditional anxiolytics.

Selank is not approved by the FDA for human therapeutic use in the United States, and Western research has been more limited than the substantial Russian literature base. Reported limitations include the geographic concentration of research within Russian institutions, the heterogeneity of methodologies across studies, the limited number of large Western randomized controlled trials, and translation barriers in accessing the full Russian literature base. Long-term safety data exists primarily within Russian clinical observation rather than formal long-duration controlled trials.

⚠️ This is an unofficial community research summary. Not affiliated with or endorsed by Amino Club. For research and educational purposes only. Not medical advice. Products discussed are not intended for human consumption.